



(11) **EP 3 811 927 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 84

(51) International Patent Classification (IPC):
A61K 9/00 ^(2006.01) **A61K 9/08** ^(2006.01)
A61K 38/09 ^(2006.01) **A61K 47/12** ^(2006.01)
A61P 15/00 ^(2006.01)

(48) Corrigendum issued on:
23.02.2022 Bulletin 2022/08

(52) Cooperative Patent Classification (CPC):
A61K 9/0019; A61K 9/08; A61K 38/09;
A61K 47/12; A61P 15/00

(45) Date of publication and mention
of the grant of the patent:
17.11.2021 Bulletin 2021/46

(21) Application number: **20162018.4**

(22) Date of filing: **10.03.2020**

(54) **A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE**

STABILE PARENTERALE DOSIERUNGSFORM VON CETRORELIXACETAT

FORME POSOLOGIQUE PARENTÉRALE STABLE D'ACÉTATE DE CÉTRORÉLIX

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

- **AGRAWAL, Sudeep**
390 012 Baroda (IN)
- **BHOWMICK, Subhas Balaram**
390 012 Baroda (IN)
- **YADAV, Arunkumar**
390 012 Baroda (IN)
- **THENNATI, Rajamannar**
390 012 Baroda (IN)

(30) Priority: **24.10.2019 IN 201921043355**

(74) Representative: **Harrison IP Limited**
3 Ebor House
Millfield Lane
Nether Poppleton, York YO26 6QY (GB)

(43) Date of publication of application:
28.04.2021 Bulletin 2021/17

(73) Proprietor: **Sun Pharmaceutical Industries Ltd**
400063 Mumbai, Maharashtra (IN)

(56) References cited:
US-A1- 2013 303 464 US-B2- 7 718 599

(72) Inventors:

- **JOSHI, Jaydip**
390 012 Baroda (IN)
- **THUMMAR, Rakesh**
390 012 Baroda (IN)

Remarks:
The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).